Defining the role of the Peripheral Benzodiazepine Receptor/translocator protein (TSPO) in inflammatory and stress responses in microglial cellsby comparative analysis

通过比较分析确定外周苯二氮卓受体/易位蛋白(TSPO)在小胶质细胞炎症和应激反应中的作用

基本信息

  • 批准号:
    9759746
  • 负责人:
  • 金额:
    $ 22.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-15 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

Ligands of the translocator protein, TSPO, are sensitive and specific biomarkers and powerful imaging agents of neurological damage. But in spite of more than 30 years of study, the function of this ancient conserved protein that is ubiquitously expressed in all kingdoms of life, remains unclear. A common theme in many different organisms is upregulation of TSPO in response to stress. In this context, we are proposing a new role for TSPO as a promoter of neuroprotection via activation of M2 microglia cells, which play a major role in neuroinflammatory diseases such as Alzheimer’s and Parkinson’s. Our goal is to characterize the activation and stress responses of microglia cells from human and mouse and to explore the role of TSPO and its ligands in this response. We will use RNAseq to determine a common expression signature and CRISPER Cas9 to test the effects of TSPO deletion and mutation on that signature (Aim1). An important tool for guiding and empowering this effort is the availability of high resolution crystal structures of the bacterial homolog of human TSPO from Rhodobacter sphaeroides, whose structure we have solved in a lipidic environment in native and mutant forms. This protein is well conserved and accessible for mutagenesis, purification, crystallization and biochemical analysis. Further, a functional assay has been developed based on Rhodobacter’s TSPO-dependent resistance to metal toxicity, which will allow us to screen mutant forms as well as various ligands to guide our intervention in the microglial system (Aim 2). Although first recognized in mitochondria as an outer membrane protein that bound benzodiazepine drugs, mounting evidence suggests TSPO involvement in a number of complex cellular processes, including cholesterol transport, porphyrin transport, tumor progression, neuroinflammation and Alzheimer’s disease. The strength of the proposal is the structure-guided comparative analysis of several systems in which TSPO is highly induced in association with inflammation and stress. This common theme among different organisms holds the potential for revealing unique insights into mechanism. A clear mechanistic relationship between TSPO structure and function will provide the basis for developing novel structure-based ligands for detection and treatment of neurological disease.
转运蛋白的配体TSPO是一种灵敏、特异的生物标志物

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
TSPO protein binding partners in bacteria, animals, and plants.
New TSPO Crystal Structures of Mutant and Heme-Bound Forms with Altered Flexibility, Ligand Binding, and Porphyrin Degradation Activity.
  • DOI:
    10.1021/acs.biochem.2c00612
  • 发表时间:
    2023-04-04
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Liu, Jian;Hiser, Carrie;Li, Fei;Hall, Robert;Garavito, R. Michael;Ferguson-Miller, Shelagh
  • 通讯作者:
    Ferguson-Miller, Shelagh
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHELAGH M FERGUSON-MILLER其他文献

SHELAGH M FERGUSON-MILLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHELAGH M FERGUSON-MILLER', 18)}}的其他基金

INVESTIGATION OF SPECTRAL CHANGES OF CYTOCHROME C OXIDASE UPON X-RAY IRRADIATION
X射线照射下细胞色素C氧化酶光谱变化的研究
  • 批准号:
    8171992
  • 财政年份:
    2010
  • 资助金额:
    $ 22.68万
  • 项目类别:
INVESTIGATION OF SPECTRAL CHANGES OF CYTOCHROME C OXIDASE UPON X-RAY IRRADIATION
X射线照射下细胞色素C氧化酶光谱变化的研究
  • 批准号:
    7956837
  • 财政年份:
    2009
  • 资助金额:
    $ 22.68万
  • 项目类别:
ENERGY TRANSDUCTION IN CYTOCHROME OXIDASE
细胞色素氧化酶中的能量转导
  • 批准号:
    7930214
  • 财政年份:
    2009
  • 资助金额:
    $ 22.68万
  • 项目类别:
INVESTIGATION OF SPECTRAL CHANGES OF CYTOCHROME C OXIDASE UPON X-RAY IRRADIATION
X射线照射下细胞色素C氧化酶光谱变化的研究
  • 批准号:
    7956801
  • 财政年份:
    2009
  • 资助金额:
    $ 22.68万
  • 项目类别:
STRUCTURAL ANALYSIS OF THE MEMBRANE METALLOPROTEIN CYTOCHROME C OXIDASE IN
膜金属蛋白细胞色素C氧化酶的结构分析
  • 批准号:
    7726019
  • 财政年份:
    2008
  • 资助金额:
    $ 22.68万
  • 项目类别:
HIGH PRESSURE COOLING OF CYTOCHROME C OXIDASE
细胞色素 C 氧化酶的高压冷却
  • 批准号:
    7357733
  • 财政年份:
    2006
  • 资助金额:
    $ 22.68万
  • 项目类别:
SUBSTRATE DOCKING IN CYTOCHROME C OXIDASE
细胞色素 C 氧化酶中的底物对接
  • 批准号:
    6316674
  • 财政年份:
    2000
  • 资助金额:
    $ 22.68万
  • 项目类别:
SUBSTRATE DOCKING IN CYTOCHROME C OXIDASE
细胞色素 C 氧化酶中的底物对接
  • 批准号:
    6107869
  • 财政年份:
    1999
  • 资助金额:
    $ 22.68万
  • 项目类别:
SUBSTRATE DOCKING IN CYTOCHROME C OXIDASE
细胞色素 C 氧化酶中的底物对接
  • 批准号:
    6271921
  • 财政年份:
    1998
  • 资助金额:
    $ 22.68万
  • 项目类别:
OXYGEN UTILIZING MEMBRANE HEME PROTEINS
利用膜血红素蛋白供氧
  • 批准号:
    6519864
  • 财政年份:
    1998
  • 资助金额:
    $ 22.68万
  • 项目类别:

相似海外基金

Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
  • 批准号:
    10412227
  • 财政年份:
    2022
  • 资助金额:
    $ 22.68万
  • 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
  • 批准号:
    10610473
  • 财政年份:
    2022
  • 资助金额:
    $ 22.68万
  • 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
  • 批准号:
    10799162
  • 财政年份:
    2022
  • 资助金额:
    $ 22.68万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6639179
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6724797
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6636512
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6326889
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6266928
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
  • 批准号:
    6539099
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
  • 批准号:
    6520329
  • 财政年份:
    2001
  • 资助金额:
    $ 22.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了